|
1
|
Tuettenberg J, Friedel C and Vajkoczy P:
Angiogenesis in malignant glioma - a target for antitumor therapy?
Crit Rev Oncol Hematol. 59:181–193. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jain RK, di Tomaso E, Duda DG, Loeffler
JS, Sorensen AG and Batchelor TT: Angiogenesis in brain tumours.
Nat Rev Neurosci. 8:610–622. 2007. View
Article : Google Scholar
|
|
3
|
Vajkoczy P and Menger MD: Vascular
microenvironment in gliomas. J Neurooncol. 50:99–108. 2000.
View Article : Google Scholar
|
|
4
|
Norden AD, Young GS, Setayesh K,
Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B,
Drappatz J, Kesari S and Wen PY: Bevacizumab for recurrent
malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Neurology. 70:779–787. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Batchelor TT, Duda DG, di Tomaso E,
Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J,
Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A,
Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY and Jain RK:
Phase II study of cediranib, an oral pan-vascular endothelial
growth factor receptor tyrosine kinase inhibitor, in patients with
recurrent glioblastoma. J Clin Oncol. 28:2817–2823. 2010.
View Article : Google Scholar
|
|
6
|
Nyberg P, Xie L and Kalluri R: Endogenous
inhibitors of angiogenesis. Cancer Res. 65:3967–3979. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Folkman J: Endogenous angiogenesis
inhibitors. APMIS. 112:496–507. 2004. View Article : Google Scholar
|
|
8
|
Cao Y: Endogenous angiogenesis inhibitors
and their therapeutic implications. Int J Biochem Cell Biol.
33:357–369. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Staton CA, Brown NJ, Rodgers GR, Corke KP,
Tazzyman S, Underwood JC and Lewis CE: Alphastatin, a 24-amino acid
fragment of human fibrinogen, is a potent new inhibitor of
activated endothelial cells in vitro and in vivo. Blood.
103:601–606. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Y, Qiu S, Song L, Yan Q and Yang G:
Secretory expression of p53(N15)-Ant following lentivirus-mediated
gene transfer induces cell death in human cancer cells. Cancer
Invest. 26:28–34. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guo SW, Che HM and Li WZ: Anti-tumor
effect of lentivirus-mediated gene transfer of alphastatin on human
glioma. Cancer Sci. 102:1038–1044. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xiaojiang T, Jinsong Z, Jiansheng W,
Chengen P, Guangxiao Y and Quanying W: Adeno-associated virus
harboring fusion gene NT4-ant-shepherdin induces cell death in
human lung cancer cells. Cancer Invest. 28:465–471. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Marr RA, Rockenstein E, Mukherjee A, Kindy
MS, Hersh LB, Gage FH, Verma IM and Masliah E: Neprilysin gene
transfer reduces human amyloid pathology in transgenic mice. J
Neurosci. 23:1992–1996. 2003.PubMed/NCBI
|
|
14
|
Malinda KM, Ponce L, Kleinman HK,
Shackelton LM and Millis AJ: Gp38k, a protein synthesized by
vascular smooth muscle cells, stimulates directional migration of
human umbilical vein endothelial cells. Exp Cell Res. 250:168–173.
1999. View Article : Google Scholar
|
|
15
|
Liu J, Kolath J, Anderson J, Kolar C,
Lawson TA, Talmadge J and Gmeiner WH: Positive interaction between
5-FU and FdUMP[10] in the inhibition of human colorectal tumor cell
proliferation. Antisense Nucleic Acid Drug Dev. 9:481–486.
1999.PubMed/NCBI
|
|
16
|
Wright TJ, Leach L, Shaw PE and Jones P:
Dynamics of vascular endothelial-cadherin and beta-catenin
localization by vascular endothelial growth factor-induced
angiogenesis in human umbilical vein cells. Exp Cell Res.
280:159–168. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Grosios K, Holwell SE, McGown AT, Pettit
GR and Bibby MC: In vivo and in vitro evaluation of combretastatin
A-4 and its sodium phosphate prodrug. Br J Cancer. 81:1318–1327.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Beckstead JH: A simple technique for
preservation of fixation-sensitive antigens in paraffin-embedded
tissues. J Histochem Cytochem. 42:1127–1134. 1994. View Article : Google Scholar
|
|
19
|
Naldini L, Blömer U, Gallay P, Ory D,
Mulligan R, Gage FH, Verma IM and Trono D: In vivo gene delivery
and stable transduction of nondividing cells by a lentiviral
vector. Science. 272:263–267. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schlegel R, Tralka TS, Willingham MC and
Pastan I: Inhibition of VSV binding and infectivity by
phosphatidylserine: is phosphatidylserine a VSV-binding site? Cell.
32:639–646. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zufferey R, Dull T, Mandel RJ, Bukovsky A,
Quiroz D, Naldini L and Trono D: Self-inactivating lentivirus
vector for safe and efficient in vivo gene delivery. J Virol.
72:9873–9880. 1998.PubMed/NCBI
|
|
22
|
Nagai K, Oubridge C, Kuglstatter A,
Menichelli E, Isel C and Jovine L: Structure, function and
evolution of the signal recognition particle. EMBO J. 22:3479–3485.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Müller JP, Bron S, Venema G and van Dijl
JM: Chaperone-like activities of the CsaA protein of Bacillus
subtilis. Microbiology. 146:77–88. 2000.PubMed/NCBI
|
|
24
|
Tjalsma H, Antelmann H, Jongbloed JD,
Braun PG, Darmon E, Dorenbos R, Dubois JY, Westers H, Zanen G, Quax
WJ, Kuipers OP, Bron S, Hecker M and van Dijl JM: Proteomics of
protein secretion by Bacillus subtilis: separating the
‘secrets’ of the secretome. Microbiol Mol Biol Rev. 68:207–233.
2004. View Article : Google Scholar
|
|
25
|
Zanen G, Antelmann H, Meima R, Jongbloed
JD, Kolkman M, Hecker M, van Dijl JM and Quax WJ: Proteomic
dissection of potential signal recognition particle dependence in
protein secretion by Bacillus subtilis. Proteomics.
6:3636–3648. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fan G, Egles C, Sun Y, Minichiello L,
Renger JJ, Klein R, Liu G and Jaenisch R: Knocking the NT4 gene
into the BDNF locus rescues BDNF-deficient mice and reveals
distinct NT4 and BDNF activities. Nat Neurosci. 3:350–357. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Corada M, Mariotti M, Thurston G, Smith K,
Kunkel R, Brockhaus M, Lampugnani MG, Martin-Padura I, Stoppacciaro
A, Ruco L, McDonald DM, Ward PA and Dejana E: Vascular
endothelial-cadherin is an important determinant of microvascular
integrity in vivo. Proc Natl Acad Sci USA. 96:9815–9820. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Carmeliet P, Lampugnani MG, Moons L,
Breviario F, Compernolle V, Bono F, Balconi G, Spagnuolo R,
Oosthuyse B, Dewerchin M, Zanetti A, Angellilo A, Mattot V, Nuyens
D, Lutgens E, Clotman F, de Ruiter MC, Gittenberger-de Groot A,
Poelmann R, Lupu F, Herbert JM, Collen D and Dejana E: Targeted
deficiency or cytosolic truncation of the VE-cadherin gene in mice
impairs VEGF-mediated endothelial survival and angiogenesis. Cell.
98:147–157. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dejana E, Bazzoni G and Lampugnani MG:
Vascular endothelial (VE)-cadherin: only an intercellular glue? Exp
Cell Res. 252:13–19. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dejana E, Spagnuolo R and Bazzoni G:
Interendothelial junctions and their role in the control of
angiogenesis, vascular permeability and leukocyte transmigration.
Thromb Haemost. 86:308–315. 2001.PubMed/NCBI
|
|
31
|
Stevens T, Garcia JG, Shasby DM,
Bhattacharya J and Malik AB: Mechanisms regulating endothelial cell
barrier function. Am J Physiol Lung Cell Mol Physiol.
279:L419–L422. 2000.PubMed/NCBI
|
|
32
|
Liao F, Li Y, O'Connor W, Zanetta L, Bassi
R, Santiago A, Overholser J, Hooper A, Mignatti P, Dejana E,
Hicklin DJ and Bohlen P: Monoclonal antibody to vascular
endothelial-cadherin is a potent inhibitor of angiogenesis, tumor
growth, and metastasis. Cancer Res. 60:6805–6810. 2000.PubMed/NCBI
|
|
33
|
Liao F, Doody JF, Overholser J, Finnerty
B, Bassi R, Wu Y, Dejana E, Kussie P, Bohlen P and Hicklin DJ:
Selective targeting of angiogenic tumor vasculature by vascular
endothelial-cadherin antibody inhibits tumor growth without
affecting vascular permeability. Cancer Res. 62:2567–2575.
2002.
|
|
34
|
Corada M, Zanetta L, Orsenigo F, Breviario
F, Lampugnani MG, Bernasconi S, Liao F, Hicklin DJ, Bohlen P and
Dejana E: A monoclonal antibody to vascular endothelial-cadherin
inhibits tumor angiogenesis without side effects on endothelial
permeability. Blood. 100:905–911. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pierce M, Wang C, Stump M and Kamb A:
Overexpression of the beta-catenin binding domain of cadherin
selectively kills colorectal cancer cells. Int J Cancer.
107:229–237. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Abraham S, Yeo M, Montero-Balaguer M,
Paterson H, Dejana E, Marshall CJ and Mavria G:
VE-Cadherin-mediated cell-cell interaction suppresses sprouting via
signaling to MLC2 phosphorylation. Curr Biol. 19:668–674. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hatanaka K, Simons M and Murakami M:
Phosphorylation of VE-cadherin controls endothelial phenotypes via
p120-catenin coupling and Rac1 activation. Am J Physiol Heart Circ
Physiol. 300:H162–H172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fukuhra S, Sakurai A, Yamagishi A, Sako K
and Mochizuki N: Vascular endothelial cadherin-mediated cell-cell
adhesion regulated by a small GTPase, Rap1. J Biochem Mol Biol.
39:132–139. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xiao K, Garner J, Buckley KM, Vincent PA,
Chiasson CM, Dejana E, Faundez V and Kowalczyk AP: p120-Catenin
regulates clathrin-dependent endocytosis of VE-cadherin. Mol Biol
Cell. 16:5141–5151. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wu JC, Yan HC, Chen WT, Chen WH, Wang CJ,
Chi YC and Kao WY: JNK signaling pathway is required for
bFGF-mediated surface cadherin downregulation on HUVEC. Exp Cell
Res. 314:421–429. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Grazia Lampugnani M, Zanetti A, Corada M,
Takahashi T, Balconi G, Breviario F, Orsenigo F, Cattelino A,
Kemler R, Daniel TO and Dejana E: Contact inhibition of
VEGF-induced proliferation requires vascular endothelial cadherin,
beta-catenin, and the phosphatase DEP-1/CD148. J Cell Biol.
161:793–804. 2003.PubMed/NCBI
|
